New model for the induction of osteoblastic bone metastases in rat

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 1067-1073

  Liepe, Knut ^a   Geidel, H ^a   Haase, M ^a   Hakenberg, O W ^a   Runge, R ^a   Kotzerke, J ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Animal study; Intra osseous application; Osteoblastic bone metastases

Indexed keywords

OXIDRONATE TECHNETIUM TC 99M;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BONE METASTASIS; BONE SCINTISCANNING; BONE TISSUE; CAVA VEIN; CLIP; CONTROLLED STUDY; DISEASE MODEL; FOLLOW UP; HEART LEFT VENTRICLE; HISTOPATHOLOGY; LUMBAR SPINE; LUNG PARENCHYMA; MALE; MOTOR DYSFUNCTION; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; RAT; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANIMALS; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; MALE; OSTEOBLASTS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RATS; TECHNETIUM TC 99M MEDRONATE;

EID: 17444419735     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 49: 8-31, 31, 1999.
2. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN and Edwards BK: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95: 1276-1299, 2003.
3. Carlin BI and Andriole GL: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88: 2989-2994, 2000.
4. Pentyala SN, Lee J, Hsieh K, Waltzer WC, Trocchia A, Musacchia L, Rebecchi MJ and Khan SA: Prostate cancer: a comprehensive review. Med Oncol 17: 85-105, 2000.
5. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC and Mihatsch MJ: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31: 578-583, 2000.
6. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593, 2002.
7. Rabbani SA, Gladu J, Harakidas P, Jamison B and Goltzman D: Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int J Cancer 80: 257-264, 1999.
8. Garrett IR: Bone destruction in cancer. Semin Oncol 20: 4-9, 1993.
9. Zhang Y, Fujita N, Oh-hara T, Morinaga Y, Nakagawa T, Yamada M and Tsuruo T: Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis. Oncogene 16: 693-703, 1998.
10. Scher HI and Yagoda A: Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibitors. Am J Med 82: 6-28, 1987.
11. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ and Taichman RS: Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metast Rev 20: 333-349, 2001.
12. Magro C, Orr FW, Manishen WJ, Sivananthan K and Mokashi SS: Adhesion, chemotaxis, and aggregation of Walker carcinosarcoma cells in response to products of resorbing bone. J Natl Cancer Inst 74: 829-838, 1985.
13. Cramer SF, Fried L and Carter KJ: The cellular basis of metastatic bone disease in patients with lung cancer. Cancer 48: 2649-2660, 1981.
14. Eilon G and Mundy GR: Association of increased cyclic adenosine 3′:5′-monophosphate content in cultured human breast cancer cells and release of hydrolytic enzymes and bone-resorbing activity. Cancer Res 43: 5792-5794, 1983.
15. Durie BG, Salmon SE and Mundy GR: Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. Br J Haematol 47: 21-30, 1981.
16. Ibbotson KJ, Twardzik DR, D'Souza SM, Hargreaves WR, Todaro GJ and Mundy GR: Stimulation of bone resorption in vitro by synthetic transforming growth factor-alpha. Science 228: 1007-1009, 1985.
17. Hirshorn JE, Vrhovsek E and Posen S: Carcinoma of the breast associated with hypercalcemia and the presence of parathyroid hormone-like substances in the tumor. J Clin Endocrinol Metab 48: 217-221, 1979.
18. Bertolini DR, Nedwin GE, Bringman TS, Smith DD and Mundy GR: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319: 516-518, 1986.
19. Canalis E: Effect of growth factors on bone cell replication and differentiation. Clin Orthop 246-263, 1985.
20. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T and Ogata E: Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 757: 539-543, 1997.
21. Demers LM, Costa L and Lipton A: Biochemical markers and skeletal metastases. Cancer 88: 2919-2926, 2000.
22. Liepe K, Hliscs R, Kropp J, Runge R, Knapp FFJr and Franke WG: Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med 44: 953-960, 2003.
23. Geldof AA, Rao BR and de Voogt HJ: Development of an in-vivo clonogenic cell assay for rat prostate metastatic tumor-R3327-MatLyLu. Urol Res 15: 139-144, 1987.
24. Haq M, Goltzman D, Tremblay G and Brodt P: Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res 52: 4613-4619, 1992.
25. Geldof AA and Rao BR: Prostatic tumor (R3327) skeletal metastasis. Prostate 16: 279-290, 1990.
26. Blomme EA, Dougherty KM, Pienta KJ, Capen CC, Rosol TJ and McCauley LK: Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. Prostate 39: 187-197, 1999.
27. Dunning WF: Prostate cancer in the rat. Natl Cancer Inst Monogr 12: 351-369, 1963.
28. Isaacs JT, Yu GW and Coffey DS: The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor. Invest Urol 19: 20-23, 1981.
29. Isaacs JT, Isaacs WB, Feitz WF and Scheres J: Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261-281, 1986.
30. Geldof AA, Rao BR and de Voogt HJ: Direct effects of chemotherapeutic agents on rat prostate tumor clonogenic cells. Anticancer Res 6: 837-840, 1986.
31. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G and Navone NM: Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61: 5652-5659, 2001.
32. Nam RK, Jewett MA and Krahn MDS: Prostate cancer: 2. Natural history. CMAJ 759: 685-691, 1998.
33. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D and Angeli A: Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol 166: 2023-2031, 2001.
34. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M et al: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164: 1248-1253, 2000.
35. Goltzmann D: Mechanisms of the development of osteoblastic metastases. Cancer 80(Suppl): 1581-1587, 1997.
36. Mundy GR: Mechanisms of bone metastasis. Cancer 80(Suppl): 1546-1556, 1997.
37. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW and Finkelstein JS: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 91: 2238-2245, 2001.
38. Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 757: 439-444, 1997.
39. Smith MR: Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 60(Suppl 1), 2002.
40. Saad F and Schulman C: Role of bisphosphonates in prostate cancer. Eur Urol 45: 26-34, 2004.
41. Goltzman D: Extending preclinical models of skeletal manifestations of malignancy to the clinical setting. Semin Oncol 28: 9-14, 2001.
42. Koutsilieris M: PA-III rat prostate adenocarcinoma cells (review). In Vivo 6: 199-203, 1992.
43. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S and Chung LW: LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44: 91-103, 2000.
44. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ and Chung LW: Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93: 15152-15157, 1996.
45. Geldof AA, van den Tillaar PL, Newling DW and Teule G: Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model. Urology 49: 795-801, 1997.
46. Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe T, Nagai K, Hatano T, Ogawa Y and Ochiai: A. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 63: 2096-2102, 2003.